Nephrotic syndrome is a kidney disorder defined by collection of symptoms such as proteinuria, hyperlipidemia, hypoalbuminia, edema, and various other complications. It develops following a pathological injury caused to the renal glomeruli, which damages the basement membrane in the renal glomeruli. The renal glomeruli filter waste and excess water from the blood. Risk factors for nephrotic syndrome may be a primary cause, with the disease being specific to the kidneys. Secondary factors include hepatitis C, diabetes, malaria, systemic lupus, HIV, hepatitis B, congenital infections, or abuse of certain drugs. 

Factors driving the global nephrotic syndrome market include increasing incidence and prevalence of nephrotic syndrome worldwide, growing elderly population, high rate of incidence hyperlipidemia, and increasing number of individuals suffering from diabetes. Moreover, other complications such as thromboembolism, HIV, hepatitis B, and hepatitis C also contribute toward the increasing rate of incidence and prevalence of nephrotic syndrome worldwide. The market for nephrotic syndrome is primarily driven by presence of a large patient pool suffering from nephrotic syndrome. According to the WHO, more than 1.4 million people worldwide undergo renal replacement therapy every year, with the rate of incidence of chronic kidney disease (CKD) rising by approximately 8% annually. However, increase in the health care expenditure and stringent regulatory approvals are likely to be restraining factors for the nephrotic syndrome market in the near future. 

The global nephrotic syndrome market can be segmented based on drug, and geography. In terms of drug, the market can be classified into sodium restriction drugs, fluid restriction drugs, loop diuretics, angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker therapy), and others. The pipeline of drugs for nephrotic syndrome is relatively small with a total of around 10 products undergoing active development in companies/institutes/universities. Of the 10 pipeline products, mostly acting on the cause effect of nephrotic syndrome, meaning they act on molecular targets not yet present in any market in the pharmaceutical industry, that are expected to become blockbuster drugs for the indication during the forecast period, generating further market growth within the nephrotic syndrome market. 

Geographically, the global nephropathic syndrome market can be categorized into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a major share of the global nephrotic syndrome market in 2017. Increase in the prevalence of nephrotic syndrome among infants, rise in funding for research, and growth in awareness about effects of the disease are likely to drive the nephrotic syndrome market in North America during the forecast period. The National Institutes of Health Office of Rare Diseases and the National Institutes of Diabetes, Digestive & Kidney Diseases have renewed the second 5-year funding cycle of the Nephrotic Syndrome Study Network, known as NEPTUNE, by offering a grant of US$ 5.8 Mn to the University of Michigan. The University of Michigan is contributing US$ 4.2 Mn over a 5-year period. Europe and Asia Pacific are projected to gain market share during the forecast period. These regions are likely to account for a significant share of the global market, in terms of revenue, in the near future. Initiatives by local governments to attain self-sufficiency in the production of pharmaceuticals and financial support for research and development of drugs for nephrotic syndrome in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa throughout the forecast period. 

Major players operating in the global nephrotic syndrome market are Asahi Kasei Pharma Corp, Bristol-Myers Squibb Co, Orbis Biosciences Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Mallinckrodt LLC, Novartis AG and Retrophin, Inc. Companies are adopting organic and inorganic growth strategies to expand their product offerings; enhance their geographical reach; expand their customer base; and gain market share. In 2014, Anthera Pharmaceuticals, Inc. and Zenyaku Kogyo Co., Ltd. entered into an exclusive licensing agreement for development and commercialization of subcutaneous blisibimod in Japan and other countries across Asia.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.